Difference between revisions of "Oxaliplatin (Eloxatin)"
Jump to navigation
Jump to search
m (→References) |
m |
||
| Line 7: | Line 7: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | |||
*[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)]] | *[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)]] | ||
*[[Colon cancer]] | *[[Colon cancer]] | ||
| + | *[[Diffuse large B-cell lymphoma]] | ||
*[[Esophageal cancer]] | *[[Esophageal cancer]] | ||
| + | *[[Extranodal NK/T-cell lymphoma, nasal type]] | ||
*[[Hepatobiliary cancer]] | *[[Hepatobiliary cancer]] | ||
*[[Pancreatic cancer]] | *[[Pancreatic cancer]] | ||
*[[Rectal cancer]] | *[[Rectal cancer]] | ||
| − | |||
*[[Testicular cancer]] | *[[Testicular cancer]] | ||
| + | *[[Transformed lymphoma]] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 38: | Line 39: | ||
[[Category:Platinum agents]] | [[Category:Platinum agents]] | ||
| − | |||
[[Category:Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications]] | [[Category:Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications]] | ||
[[Category:Colon cancer medications]] | [[Category:Colon cancer medications]] | ||
| + | [[Category:Diffuse large B-cell lymphoma medications]] | ||
[[Category:Esophageal cancer medications]] | [[Category:Esophageal cancer medications]] | ||
| + | [[Category:Extranodal NK/T-cell lymphoma, nasal type medications]] | ||
[[Category:Hepatobiliary cancer medications]] | [[Category:Hepatobiliary cancer medications]] | ||
[[Category:Pancreatic cancer medications]] | [[Category:Pancreatic cancer medications]] | ||
[[Category:Rectal cancer medications]] | [[Category:Rectal cancer medications]] | ||
| − | |||
[[Category:Testicular cancer medications]] | [[Category:Testicular cancer medications]] | ||
| + | [[Category:Transformed lymphoma medications]] | ||
[[Category:Drugs FDA approved in 2002]] | [[Category:Drugs FDA approved in 2002]] | ||
Revision as of 02:01, 14 May 2015
General information
Class/mechanism: Platinum analog, alkylating-like, which produces interstrand and intrastrand DNA crosslinks that inhibit DNA replication and transcription, causing non-cell cycle specific cytotoxicity and death.[1][2][3]
Route: IV
Extravasation: irritant (usually), vesicant (rare)
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)
- Colon cancer
- Diffuse large B-cell lymphoma
- Esophageal cancer
- Extranodal NK/T-cell lymphoma, nasal type
- Hepatobiliary cancer
- Pancreatic cancer
- Rectal cancer
- Testicular cancer
- Transformed lymphoma
Patient drug information
- Oxaliplatin (Eloxatin) package insert PDF pages 15-16[1]
- Oxaliplatin (Eloxatin) patient drug information (Chemocare)[4]
- Oxaliplatin (Eloxatin) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 8/9/2002: Initial FDA approval: "used in combination with infusional 5-FU/ LV, is indicated for the treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed during or within 6 months of completion of first line therapy with the combination of bolus 5-FU/ LV and irinotecan."
- 1/9/2004: Indication revised: "used in combination with infusional 5-FU/ LV, is indicated for the treatment of advanced carcinoma of the colon or rectum.
- 11/4/2004: New indication: "used in combination with infusional 5-FU/ LV, is indicated for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor.
Also known as
Dacotin, Dacplat, Eloxatin, Eloxatine, JM-83, RP-54780, SR-96669
References
Categories:
- Drug index
- Chemotherapy
- Intravenous chemotherapy
- Platinum agents
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications
- Colon cancer medications
- Diffuse large B-cell lymphoma medications
- Esophageal cancer medications
- Extranodal NK/T-cell lymphoma, nasal type medications
- Hepatobiliary cancer medications
- Pancreatic cancer medications
- Rectal cancer medications
- Testicular cancer medications
- Transformed lymphoma medications
- Drugs FDA approved in 2002